163 related articles for article (PubMed ID: 31983428)
1. Interaction between IDH1 WT and calmodulin and its implications for glioblastoma cell growth and migration.
Kang S; Kwon HN; Kang S; Park S
Biochem Biophys Res Commun; 2020 Mar; 524(1):224-230. PubMed ID: 31983428
[TBL] [Abstract][Full Text] [Related]
2. IDH1
Han X; Zhou H; Sun W; Hou L; Wang Y; Wang H; Lv Z; Xue X
Sci Rep; 2023 Nov; 13(1):19659. PubMed ID: 37952042
[TBL] [Abstract][Full Text] [Related]
3. Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.
Wang Q; Zhang L; Cui Y; Zhang C; Chen H; Gu J; Qian J; Luo C
Oncol Rep; 2020 Jan; 43(1):188-200. PubMed ID: 31746408
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Metabolomic Analysis of IDH1
Miyata S; Tominaga K; Sakashita E; Urabe M; Onuki Y; Gomi A; Yamaguchi T; Mieno M; Mizukami H; Kume A; Ozawa K; Watanabe E; Kawai K; Endo H
Sci Rep; 2019 Jul; 9(1):9787. PubMed ID: 31278288
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678
[TBL] [Abstract][Full Text] [Related]
6. Wild‑type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells.
Shen X; Wu S; Zhang J; Li M; Xu F; Wang A; Lei Y; Zhu G
Mol Med Rep; 2020 Sep; 22(3):1949-1957. PubMed ID: 32705169
[TBL] [Abstract][Full Text] [Related]
7. Different Effects of RNAi-Mediated Downregulation or Chemical Inhibition of NAMPT in an Isogenic IDH Mutant and Wild-Type Glioma Cell Model.
Clausing M; William D; Preussler M; Biedermann J; Grützmann K; Richter S; Buchholz F; Temme A; Schröck E; Klink B
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628596
[TBL] [Abstract][Full Text] [Related]
8. Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL.
Karpel-Massler G; Ishida CT; Bianchetti E; Zhang Y; Shu C; Tsujiuchi T; Banu MA; Garcia F; Roth KA; Bruce JN; Canoll P; Siegelin MD
Nat Commun; 2017 Oct; 8(1):1067. PubMed ID: 29057925
[TBL] [Abstract][Full Text] [Related]
9. A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.
Machida Y; Nakagawa M; Matsunaga H; Yamaguchi M; Ogawara Y; Shima Y; Yamagata K; Katsumoto T; Hattori A; Itoh M; Seki T; Nishiya Y; Nakamura K; Suzuki K; Imaoka T; Baba D; Suzuki M; Sampetrean O; Saya H; Ichimura K; Kitabayashi I
Mol Cancer Ther; 2020 Feb; 19(2):375-383. PubMed ID: 31727689
[TBL] [Abstract][Full Text] [Related]
10. Expression of R132H mutational IDH1 in human U87 glioblastoma cells affects the SREBP1a pathway and induces cellular proliferation.
Zhu J; Cui G; Chen M; Xu Q; Wang X; Zhou D; Lv S; Fu L; Wang Z; Zuo J
J Mol Neurosci; 2013 May; 50(1):165-71. PubMed ID: 23011765
[TBL] [Abstract][Full Text] [Related]
11. Evaluating Mechanisms of IDH1 Regulation through Site-Specific Acetylation Mimics.
Weeks J; Strom AI; Widjaja V; Alexander S; Pucher DK; Sohl CD
Biomolecules; 2021 May; 11(5):. PubMed ID: 34065652
[TBL] [Abstract][Full Text] [Related]
12. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C
PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098
[TBL] [Abstract][Full Text] [Related]
13. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
[TBL] [Abstract][Full Text] [Related]
14. Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate.
Dexter JP; Ward PS; Dasgupta T; Hosios AM; Gunawardena J; Vander Heiden MG
J Biol Chem; 2018 Dec; 293(52):20051-20061. PubMed ID: 30381394
[TBL] [Abstract][Full Text] [Related]
15. Increased
Koyasu S; Shimizu Y; Morinibu A; Saga T; Nakamoto Y; Togashi K; Harada H
J Neurooncol; 2019 Dec; 145(3):441-447. PubMed ID: 31667733
[TBL] [Abstract][Full Text] [Related]
16. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1
Waitkus MS; Pirozzi CJ; Moure CJ; Diplas BH; Hansen LJ; Carpenter AB; Yang R; Wang Z; Ingram BO; Karoly ED; Mohney RP; Spasojevic I; McLendon RE; Friedman HS; He Y; Bigner DD; Yan H
Cancer Res; 2018 Jan; 78(1):36-50. PubMed ID: 29097607
[TBL] [Abstract][Full Text] [Related]
17. An R132H mutation in isocitrate dehydrogenase 1 enhances p21 expression and inhibits phosphorylation of retinoblastoma protein in glioma cells.
Miyata S; Urabe M; Gomi A; Nagai M; Yamaguchi T; Tsukahara T; Mizukami H; Kume A; Ozawa K; Watanabe E
Neurol Med Chir (Tokyo); 2013; 53(10):645-54. PubMed ID: 24077277
[TBL] [Abstract][Full Text] [Related]
18. Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants.
Avellaneda Matteo D; Wells GA; Luna LA; Grunseth AJ; Zagnitko O; Scott DA; Hoang A; Luthra A; Swairjo MA; Schiffer JM; Sohl CD
Biochem J; 2018 Oct; 475(20):3221-3238. PubMed ID: 30249606
[TBL] [Abstract][Full Text] [Related]
19. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
[TBL] [Abstract][Full Text] [Related]
20. IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: A case-control study.
Paldor I; Drummond KJ; Kaye AH
J Clin Neurosci; 2016 Dec; 34():117-120. PubMed ID: 27522495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]